Apellis Pharmaceuticals, Inc.
APLS
Hisse Senetlerindeki Sıralama
#3322
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical... Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Hisse Fiyatı
$41.03
Son senkronizasyon: 2026-05-15
Piyasa Değeri
$5.25B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
51.57%
Ülke
US
Ticaret Apellis Pharmaceuticals, Inc. (APLS)
Kategori
Healthcare
Apellis Pharmaceuticals, Inc. (APLS) için tedavüldeki hisse sayısı
March 2026 itibarıyla tedavüldeki hisse sayısı: 0.00
Apellis Pharmaceuticals, Inc. şirketinin son finansal raporlarına ve hisse fiyatına göre, mevcut tedavüldeki hisse sayısı 0.00'dir. December 2023 sonunda şirketin 118.68M tedavüldeki hissesi vardı. Tedavüldeki hisse sayısı genellikle hisse bölünmeleri ve hisse geri alımları ile etkilenir.
Apellis Pharmaceuticals, Inc. (APLS) için 2013 - 2026 tarihleri arasındaki hisse geçmişi
Her yıl sonunda tedavüldeki hisse sayısı
| Yıl | Tedavüldeki Hisse Sayısı | Değiştir |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2024 | 123.91M | 4.40% |
| 2023 | 118.68M | 11.84% |
| 2022 | 106.11M | 25.70% |
| 2021 | 84.42M | 12.32% |
| 2020 | 75.16M | 20.78% |
| 2019 | 62.23M | 14.40% |
| 2018 | 54.40M | 58.94% |
| 2017 | 34.22M | 89.15% |
| 2016 | 18.09M | 0.00% |
| 2015 | 18.09M | 0.00% |
| 2014 | 18.09M | 294.79% |
| 2013 | 4.58M | 0.00% |
Benzer şirketler veya rakipler için tedavüldeki hisse sayısı
| Şirket | Tedavüldeki Hisse Sayısı | Fark | Ülke |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| - | - |
CH
|
|
| 62.19M | - |
NL
|
